ASCO Annual Meeting | Conference

Dr. Byrd on Ibrutinib Versus Ofatumumab in CLL

June 1st 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising findings from the phase III RESONATE trial that compared ofatumumab to ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Investigational Immunotherapy Granted First Breakthrough Therapy Designation in Bladder Cancer

June 1st 2014

MPDL3280A reduced tumors in 43% of patients with previously treated PD-L1-positive metastatic bladder cancer, resulting in the first breakthrough therapy designation from the FDA for a treatment in this setting.

Ramucirumab Modestly Improves Survival in Advanced NSCLC

June 1st 2014

Adding the VEGFR-2 inhibitor ramucirumab to standard docetaxel improved overall survival by 1.4 months versus docetaxel alone in patients with advanced non–small cell lung cancer.

Dr. Pegram on a Phase II Trial of MGAH22 in Breast Cancer

June 1st 2014

Mark D. Pegram, MD, from the Stanford University Medical Center, discusses a phase II study of margetuximab in patients with relapsed or refractory advanced breast cancer whose tumors express HER2 at the 2+ level by immunohistochemistry and lack evidence of HER2 gene amplification by FISH.

Targeted Therapy Combination Improves PFS in Ovarian Cancer

May 31st 2014

Combining the oral targeted agents olaparib and cediranib resulted in a near-doubling of median progression-free survival (PFS) among women with recurrent ovarian cancer in a phase II study highlighted Saturday during the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

Ibrutinib Triples PFS, Doubles OS in Phase III CLL Trial

May 31st 2014

Treatment with single-agent ibrutinib dramatically increased PFS by nearly 80% and significantly extended OS by 57% compared with ofatumumab in patients with relapsed or refractory CLL.

Lenvatinib Likely to Become Standard in Resistant Differentiated Thyroid Cancer

May 31st 2014

Lenvatinib, a novel multityrosine kinase inhibitor, is highly effective against differentiated thyroid cancer that has become resistant to standard RAI therapy.

Study Supports Dialing Back Radiation for Some Patients With HPV-Positive Oropharyngeal Cancer

May 31st 2014

Patients with less aggressive, HPV-positive oropharyngeal cancer can be effectively treated with a lower-dose radiation regimen depending upon their response to combination induction therapy.

Dr. Yardley on Enzalutamide Plus Exemestane in HR-Positive Breast Cancer

May 31st 2014

Denise A. Yardley, MD, hematologist/oncologist, Sarah Cannon Research Institute discusses a pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer when given enzalutamide plus exemestane.

Goserelin Preserves Fertility, Aids Survival During Breast Cancer Chemo

May 31st 2014

Adding goserelin to chemotherapy for women with early-stage hormone receptor (HR)-negative breast cancer helps both to preserve their fertility and to prolong their survival.

Early Palliative Care for Caregivers Improves Their Wellbeing, Too

May 31st 2014

A phone-based intervention that offers practical tools to help family caregivers support their loved one with advanced cancer-as well as emphasizing the importance of maintaining a healthy lifestyle themselves-resulted in less caregiver depression and better quality of life, according to the findings of a new study presented May 30 at the 50th Annual ASCO Meeting in Chicago.

Zoledronic Acid Can Be Administered Less Frequently in Breast Cancer

May 31st 2014

The dosing frequency of zoledronic acid can be reduced by 67% without compromising efficacy and safety in women with breast cancer and bone metastases.

Dr. Hussain on ETS Gene Fusions as a Predictive Biomarker in Prostate Cancer

May 31st 2014

Maha Hussain, MD, from the University of Michigan Comprehensive Cancer Center, discusses the possibility of ETS gene fusions acting as a predictive biomarker for prostate cancer.

Reducing Pills From the Cup: Discontinuing Statins in Late-Stage Cancer Patients

May 31st 2014

For patients with less than a year to live, the discontinuation of statins may increase the median time-to-death and improve quality of life.

Dr. Formenti on Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy in TNBC

May 29th 2014

Silvia Formenti, MD, The Sandra and Edward H. Meyer Professor of Radiation Oncology chair, Radiation Oncology, NYU Langone Medical Center, associate director, Radiation Oncology, Perlmutter Cancer Center at NYU Langone, discusses a trial that examines concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer (TNBC)

Dr. Pavlick on a Phase II Trial of Cyclophosphamide and Ipilimumab in Melanoma

May 28th 2014

Anna C. Pavlick, DO, associate professor, Hematology and Medical Oncology, medical director, Clinical Trials Office, Perlmutter Cancer Center at NYU Langone, discusses a phase II trial exploring low-dose cyclophosphamide and ipilimumab in metastatic melanoma.

Dr. Luke Discusses the Phase III COMBI-d Trial Results

May 24th 2014

Jason J. Luke, MD, instructor, Department of Medicine, Harvard School of Medicine, staff physician, medical oncologist- melanoma, Dana-Farber Cancer Institute, discusses the controversy behind the COMBI-d trial results.

As Lung Cancer Screening Debate Continues, Study Projects Implementation Outcomes

May 14th 2014

In December 2013, the US Preventive Services Task Force (USPSTF) recommended that asymptomatic, high-risk individuals receive annual screening for lung cancer with low-dose computed tomography (LDCT).

Novel TKI May Provide New Treatment Option for Patients With Recurrent PVNS

May 14th 2014

The new targeted drug, PLX3397, has demonstrated responses in patients with pigmented villonodular synovitis (PVNS), a rare joint disorder.

For Premenopausal Women With ER-Positive Disease, Obesity Is a Major Risk Factor in Breast Cancer Mortality

May 14th 2014

Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease.

NEXT PAGE
PREVIOUS PAGE